Efficacy of combined use of glycosaminoglycan peptide complex for intramuscular administration and oral diacerein in osteoarthritis: evaluation according to an observational multicenter clinical trial
Эффективность комбинированного применения гликозаминогликан-пептидного комплекса для внутримышечного введения и диацереина для приема внутрь при остеоартрите: оценка по данным многоцентрового наблюдательного клинического исследования
2021-05-15
SCID: 54.1/d9vvyru5
Discuss with AI
diacereinglycosaminoglycan peptide complexintramuscular administrationmulticenter observational trialosteoarthritis
Figures from the paper
Abstract (AI)
BACKGROUND: The combined use of intramuscular injection glycosaminoglycan peptide complex (GPC) and oral diacerein can increase the effectiveness of treatment of osteoarthritis (OA). AIM: Compare the effectiveness of combination GPC + diacerein and GPC monotherapy in the treatment of OA in clinical practice. MATERIALS AND METHODS: A retrospective evaluation of the results of a 12-week multicenter observational non-interventional study of the effectiveness of GPC (Rumalon, a course of intramuscular injections 3 times a week, №25) in patients with moderate/severe OA (n=2955) requiring regular administration of nonsteroidal anti-inflammatory drugs (NSAIDs). The analysis identified a group of patients (n=414) who received GPC in combination with diacerein 100 mg/day (Diaflex Rompharm). The therapeutic effect was compared in the groups of GPC monotherapy (n=2541) and the combination of GPC with diacerein. These groups did not differ in average age (61.411.8 and 61.911.3 years), both were dominated by women (76.3 and 70.3%), there was approximately equal intensity of pain during movement and impaired joint function: 6.11.8/6.01.6 and 4.92.1/5.11.8 (according to the numerical rating scale 010). The dynamics of pain intensity, the need for NSAIDs, and the frequency of adverse events (AE) were compared 12 weeks after the start of treatment. RESULTS AND DISCUSSION: In the majority of patients with OA both on the background of GPC monotherapy and combined use of GPC and diacerein, there was a significant improvement. The number of patients with pain reduction 50% was 54.3 and 62.8% (p0.001), NSAID administration was completely stopped in 66.7 and 77.5% (p0.001), respectively. The effectiveness of the combination of GPC and diacerein was significantly higher than that of GPC monotherapy in OA of the knee joint, hip joint, and generalized OA. AE from the gastrointestinal tract was observed in 7.8 and 8.9%, arterial hypertension in 6.3 and 4.6%, allergic reactions in 0.3 and 0.5% of patients (not significant). CONCLUSION: The application of the code of civil procedure is an effective treatment for OA. The combination of GPC and diacerein provides a more significant improvement than GPC monotherapy. GPC and diacerein (including in combination) are well tolerated and rarely cause AE.
Key Findings
1
A 12-week multicenter observational analysis included 2,955 patients with moderate-to-severe osteoarthritis requiring regular NSAIDs.
2
Both glycosaminoglycan peptide complex monotherapy and its combination with diacerein significantly improved osteoarthritis outcomes in most patients.
3
Combination therapy was significantly more effective for knee, hip, and generalized osteoarthritis, with broadly comparable adverse-event frequencies.
4
NSAID use was completely discontinued in 77.5% receiving combination therapy versus 66.7% receiving GPC alone (p<0.001).
5
Pain reduction of at least 50% occurred in 62.8% with combination therapy versus 54.3% with GPC monotherapy (p<0.001).
Research Object
Patients with moderate-to-severe osteoarthritis treated with intramuscular glycosaminoglycan peptide complex, with or without oral diacerein
Research Subject
Comparative 12-week effectiveness, pain reduction, NSAID discontinuation, and adverse-event frequency of combined GPC plus diacerein versus GPC monotherapy
Publication Details
Publication Date
2021-05-15
Journal
Publisher
ISSN
Cited by
10
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai5
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 20172018
An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)2019
Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis2019
Glycosaminoglycan-peptide complex in the treatment of knee and hip osteoarthritis: from the past to the future2020
Evaluation of the efficacy and safety of injectable glycosaminoglycan-peptide complex (GPC) in patients with osteoarthritis: a multicenter observational study GLADIOLUS (GPC in the treatment of osteoarthritis: a follow-up study of pain relief and local symptom reduction)2020